Condition
Agitation Associated With Dementia of the Alzheimer's Type
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03620981Phase 2CompletedPrimary
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
NCT03724942Phase 3CompletedPrimary
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
NCT02168920Phase 3TerminatedPrimary
Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Showing all 3 trials